Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations
Year: 2020
Type: article
Source: Journal of Thoracic Oncology
Authors: Jordi Remon, Francesco Passiglia, Myung-Ju Ahn, Fabrice Barlesi, Patrick M. Forde, Edward B. Garon, Scott Gettinger, Sarah B. Goldberg, Roy S. Herbst, Leora Horn, Kaoru Kubota, Shun Lu, Laura Mezquita, Luis Paz-Ares, Sanjay Popat, Kurt A. Schalper, Ferdinandos Skoulidis, Martin Reck, Alex A. Adjei, Giorgio V. Scagliotti
Institutions: HM Hospitales, Delfos Hospital, Ospedale San Luigi Gonzaga, University of Turin, Samsung Medical Center, Sungkyunkwan University, Centre National de la Recherche Scientifique, Inserm, Aix-Marseille Université, Centre de Recherche en Cancérologie de Marseille, Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, University of California, Los Angeles, Yale University, Vanderbilt University, Vanderbilt-Ingram Cancer Center, Nippon Medical School, Shanghai Jiao Tong University, Shanghai Chest Hospital, Institut Gustave Roussy, Fondation Gustave Roussy, Hospital Universitario 12 De Octubre, Institute of Cancer Research, Royal Marsden Hospital, Imperial College London, The University of Texas MD Anderson Cancer Center, German Center for Lung Research, LungenClinic Grosshansdorf, Mayo Clinic, Mayo Clinic Comprehensive Cancer Center (Minnesota)
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funders: Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, Bayer, Merck, Novartis, Roche, Sanofi, Ariad Pharmaceuticals, AbbVie, F. Hoffmann-La Roche, Boehringer Ingelheim, Takeda Pharmaceutical Company, Les Laboratories Pierre Fabre, Kyowa Hakko Kirin, MedImmune, Ipsen, Genentech, EMD Serono, Merck Sharp and Dohme, Ignyta
OpenAlex ID: W3010741030